Jiangsu Recbio Technology Company Description

Jiangsu Recbio Technology Co., Ltd., a vaccine company, engages in the research, development, and commercialization of subunit vaccines in the People’s Republic of China.

The company is developing vaccines for the treatment of cervical cancer, and anal and genital warts, including REC603, a recombinant human papillomavirus (HPV) 9-valent vaccine that is in phase III clinical trial; REC601 and REC602 recombinant HPV bivalent vaccines targeting HPV type 6/11, which are in phase I clinical trials; REC604a, a recombinant HPV quadrivalent vaccine that is in pre-clinical stage; and REC604b, a recombinant HPV 9-valent vaccine that is in pre-clinical stage.

It also develops ReCOV, a recombinant COVID-19 vaccine candidate that is in Phase II/III trial; REC610, a recombinant shingles vaccine that is in Phase l clinical trial; and REC617, a recombinant influenza quadrivalent vaccine that is in pre-clinical stage.

Jiangsu Recbio Technology Co., Ltd. was founded in 2012 and is headquartered in Taizhou, the People’s Republic of China.

Jiangsu Recbio Technology Co., Ltd.

Country	China
Founded	2012
Industry	Biotechnology
Sector	Healthcare
Employees	531
CEO	Yong Liu

Contact Details

Address: No. 888 Yaocheng Avenue Taizhou China
Website	recbio.cn

Stock Details

Ticker Symbol	2179
Exchange	Hong Kong Stock Exchange
Fiscal Year	January - December
Reporting Currency	CNY
ISIN Number	CNE1000057K9
SIC Code	2836

Key Executives

Name	Position
Dr. Yong Liu	Founder, Chief Executive Officer and Chairman of the Board
Qingqing Chen	Chief Financial Officer, Joint Company Secretary and Executive Director
Dr. Kunxue Hong	Chief Science Officer and Executive Director
Bu Li	Chief Human Resource Officer and Executive Director
Yang Zhou	Chief Operating Officer
Kejian Yang Ph.D.	Senior Vice Vice President and Chief Technology Officer
Hongjun Zhou	Vice General Manager
Jing Wang	Chief Quality Officer
Lei Zhou	Finance controller
Mei Yee Yung FCIS, FCS	Joint Company Secretary